U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500220) titled 'Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC' on March 17.
Brief Summary: open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.
Study Start Date: March 02
St...